Relay Therapeutics, Inc. research snapshot
RLAY AI stock analysis reads Relay Therapeutics as a high-risk, high-reward clinical-stage precision medicine company that has de-risked its lead asset zovegalisib (RLY-2608) with an FDA breakthrough therapy designation and promising early data in PIK3CA-mutant breast cancer and vascular anomalies. At the August 4, 2026 data cutoff, RLAY traded near $18.55 with a verified market capitalization near $4.04 billion, holding approximately $642 million in cash with minimal debt. The stock has rallied about 452% over the past year but pulled back from its $20.79 52-week high, and the next Q2 2026 earnings report is due August 6, 2026. A May 2026 follow-on offering at $12.00 per share raised about $275 million to extend the cash runway into 2029. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$18.55
Market cap
$4.04 billion
AI score
60 / 100
Rating
Moderate: strong clinical progress on zovegalisib, binary Phase 3 and near-term earnings risk
Trend status
Pullback within a strong uptrend after a roughly 452% one-year gain
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Relay Therapeutics combines computational protein motion analysis (Dynamo platform) and experimental drug discovery to target previously undruggable proteins. Lead asset zovegalisib holds an FDA breakthrough therapy designation, showed a median progression-free survival of 11.1 months in heavily pretreated CDK4/6-experienced breast cancer patients, and produced a volumetric response in about 60% of 20 vascular anomaly patients in phase 2 data. | Medium-high |
| Moat | The mutant-selective PI3Ka approach is designed to avoid the hyperinsulinemia toxicity of orthosteric inhibitors, which creates technical differentiation. Durability depends on clinical execution, patent protection, and whether Roche inavolisib or Novartis alpelisib can match the selectivity profile. | Medium |
| Management | Management advanced zovegalisib from discovery to Phase 3, secured a breakthrough therapy designation, outlicensed RLY-4008 to Elevar for non-dilutive capital, and raised about $275 million in May 2026 to fund operations into 2029. The tradeoff is ongoing shareholder dilution through follow-on offerings. | Medium |
| Financial trend | Pre-revenue biotech with TTM collaboration revenue of $10.7M, TTM net loss of $272.7M, and about $642M cash. Management projects the runway funds operations into 2029. Q2 2026 earnings are due August 6, 2026, with consensus expectations of a loss of $0.41 per share. | High |
| Valuation | At $18.55, RLAY trades at about 6.4x book value and roughly 307x trailing sales, with enterprise value near $3.5 billion. Valuation is based on pipeline probability-adjusted NPV rather than earnings. Analyst targets range from $20 to $31 with an average near $25 to $26. | Medium |
| Technical trend | Long-term uptrend intact with price above the 50-day SMA near $17.01 and the 200-day SMA near $11.35, but the stock pulled back below the 8-day SMA near $18.80 and the 20-day SMA near $19.22 after retreating from the $20.79 high. MACD stays positive at 0.42. | Medium-high |
| Risk level | Very high. Binary Phase 3 ReDiscover-2 readout, pre-revenue profile, equity dilution from follow-on offerings, competitive PI3Ka field, single-asset dependency, and near-term event risk around the August 6 earnings report. | High |
| AI confidence | High for descriptive facts, cash position, and market data; medium-low for forward scenarios due to binary clinical trial outcomes. | Medium confidence |
| Investment certainty | Low certainty. RLAY is suitable only for high-risk-tolerant investors who understand binary biotech risk and hold a diversified portfolio. | Low |
RLAY AI stock forecast
The RLAY AI stock forecast uses scenario ranges around the $18.55 quote. Unlike profitable companies, biotech forecasts depend on pipeline value rather than earnings growth. All scenarios are highly uncertain and depend on the Phase 3 zovegalisib readout, the August 6 Q2 earnings update, regulatory outcomes, competitive positioning, and future capital needs.
$26 to $34
More likely if ReDiscover-2 Phase 3 data confirms zovegalisib superiority in PIK3CA-mutant breast cancer, vascular anomaly data supports a second indication, the Phase 3 frontline combination trial with atirmociclib starts on schedule in early 2027, and no further dilutive financing is needed. Goldman Sachs raised its target to $31 and Canaccord Genuity initiated at $29 in July 2026.
$17 to $25
More likely if Phase 3 data is positive but not transformative, the stock trades within the analyst target range ($20 to $31, average near $25 to $26) and pipeline probability-adjusted NPV, and the August 6 earnings report does not surprise negatively.
$5 to $12
More likely if Phase 3 misses primary endpoints, safety concerns emerge in broader testing, Roche inavolisib or Novartis alpelisib keeps or expands market share, the August 6 update disappoints, or the company needs another dilutive offering below the $12.00 May 2026 offering price.
RLAY AI technical analysis
RLAY AI technical analysis shows a pullback inside a strong uptrend as of the August 4, 2026 data cutoff. The stock trades above the 50-day SMA near $17.01 and the 200-day SMA near $11.35 after a roughly 452% one-year rally from the $3.03 52-week low, but it fell below the 8-day SMA near $18.80 and the 20-day SMA near $19.22 after retreating from the $20.79 high. MACD remains positive at 0.42. The Financhill RSI feed returned an unreliable value at this cutoff, so momentum is assessed from the price position relative to moving averages.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $18.55 | Yahoo Finance intraday quote on August 4, 2026. Previous close was $18.83 on August 3, 2026. |
| Near support | $18.48 to $18.80 | The Bollinger Band (25) lower band near $18.48 and the 8-day SMA near $18.80 form the first support zone. |
| Medium support | $17.01 to $17.29 | The 50-day SMA near $17.01 and the 50-day EMA near $17.29 mark the medium support zone that has held the pullback so far. |
| Key long-term support | $11.35 to $12.32 | The 200-day SMA near $11.35 and the 200-day EMA near $12.32 define the long-term trend reference. |
| Near resistance | $19.22 to $19.76 | The 20-day SMA near $19.22 and the Bollinger Band (25) upper band near $19.76 create the immediate overhead zone. |
| Strong resistance | $20.00 to $20.79 | The round $20 level and the $20.79 52-week high cap the recent range. |
| Momentum | MACD +0.42; price below 8-day and 20-day averages | MACD remains positive, but the price position below the short-term averages signals a near-term pullback. RSI was not usable at this cutoff because the Financhill feed returned 0. |
| Volume | Average ~4.0 million shares | Yahoo Finance average volume near 3.99 million shares. Recent sessions ran below average, consistent with a low-participation pullback rather than active distribution. |
| Volatility | Beta 1.68, 52-week range $3.03 to $20.79 | High beta reflects the binary-risk biotech profile. The stock moved from $3.03 to $20.79 in 12 months. |
| Invalidation | Close below $17 | A decisive close below the 50-day SMA area near $17 would signal the pullback is deepening and put the medium-term structure under pressure. |
RLAY AI trading strategy
The RLAY AI trading strategy is a rules-based research framework for monitoring a binary-outcome biotech stock during a pullback inside a strong uptrend. It is not personal advice and should be paired with fresh trial data, filings, the August 6 earnings report, probability-weighted position sizing, and a defined invalidation level.
Watch for RLAY to reclaim the $18.80 to $19.22 moving average zone, then clear the $19.76 to $20.79 resistance zone on above-average volume. A breakout above the $20.79 52-week high could open the path toward analyst targets in the $25 to $31 range.
A close below $17, or a failed breakout after a Phase 3 or earnings catalyst, should invalidate the trend-following setup. Reduce position size before the August 6 earnings report and other binary events.
If RLAY pulls back toward the $17.01 to $17.29 50-day moving average zone without negative clinical or earnings news, compare the drawdown with overall biotech sentiment and cash position before assuming the support is durable.
Biotech stocks can gap down 30-50% on negative data or guidance. Use strict stop-losses and limit position size to a risk budget you can lose entirely.
Track the August 6, 2026 Q2 earnings report, ReDiscover-2 Phase 3 enrollment and interim readout dates, vascular anomaly data updates, the Phase 3 frontline combination trial start (expected early 2027), RLY-8161 data, cash position and dilution risk, and the competitive PI3Ka field.
Any significant delay in Phase 3 enrollment or the combination trial start is a negative signal. A secondary offering below the $12.00 May 2026 price would signal urgent capital needs.
Investment research summary
Relay Therapeutics uses computational protein motion analysis (Dynamo platform) to discover small molecule drugs for targets traditional methods cannot address. Customers are patients and physicians who need better precision medicines for genetically defined cancers and rare diseases.
The moat depends on clinical differentiation. Zovegalisib is designed as a mutant-selective PI3Ka inhibitor that avoids the hyperinsulinemia toxicity of orthosteric inhibitors like alpelisib. If Phase 3 data confirms superior tolerability with maintained efficacy, this selectivity creates a meaningful competitive advantage backed by breakthrough therapy designation.
The thesis fails if ReDiscover-2 misses primary endpoints, if Roche inavolisib or another competitor captures the PI3Ka-mutant breast cancer market first, if vascular anomaly data disappoints, if the August 6 earnings update reveals a weaker cash position, if cash requires more dilutive financing before a value inflection, or if the Dynamo platform fails to produce additional pipeline assets.
Management should be judged by clinical trial execution, capital allocation discipline (including the RLY-4008 outlicense to Elevar and the May 2026 offering at $12.00), cash runway management into 2029, and the ability to advance the pipeline beyond the lead asset. Key-person risk exists around the core computational biology and clinical development team.
Precision oncology is a secular growth trend driven by decreasing sequencing costs, expanding biomarker identification, and regulatory acceptance of targeted trial designs. PI3Ka is among the most frequently mutated kinases in cancer, and vascular anomalies add a second large addressable patient group.
At $18.55 and about $4.04B market cap, RLAY prices in meaningful probability of Phase 3 success and commercial adoption. The margin of safety is limited given the binary risk. Analyst targets ($20 to $31, average near $25 to $26) suggest the stock is below consensus fair value assuming positive Phase 3 data.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RLAY price | $18.55 intraday on August 4, 2026; previous close $18.83 on August 3, 2026 | Yahoo Finance and Google Finance | August 4, 2026 |
| Market capitalization | $4.04 billion, verified as $18.55 x 217.94 million shares (0.07% deviation) | financial_rigor.py market cap verification | August 4, 2026 |
| Cash and equivalents | $642 million | Yahoo Finance balance sheet (mrq) | August 4, 2026 |
| TTM revenue | $10.68 million (collaboration revenue) | Yahoo Finance income statement | August 4, 2026 |
| TTM net income | -$272.7 million | Yahoo Finance income statement | August 4, 2026 |
| EPS (TTM) | -$1.56 | Yahoo Finance statistics | August 4, 2026 |
| Shares outstanding | 217.94 million | Google Finance and Yahoo Finance | August 4, 2026 |
| Price/book value | 6.38x per Yahoo Finance; 6.37x calculated | financial_rigor.py valuation verification | August 4, 2026 |
| 52-week range | $3.03 to $20.79 | Yahoo Finance and Google Finance | August 4, 2026 |
| Analyst consensus | 12 analysts, all Buy; average target $25.27 (range $20.00 to $31.00); Yahoo Finance 1-year estimate $26.08 | Google Finance analyst ratings and Yahoo Finance | August 4, 2026 |
| May 2026 public offering | 22,916,667 shares at $12.00 per share, gross proceeds about $275 million | Relay Therapeutics press release (GlobeNewswire) | May 20, 2026 |
| Technical snapshot | 8-day SMA $18.80, 20-day SMA $19.22, 50-day SMA $17.01, 200-day SMA $11.35, MACD +0.42 | Financhill technical analysis snapshot | July 30, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell RLAY stock. Forecast scenarios are based on available public data, clinical trial disclosures, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. Clinical-stage biotech investments carry the risk of total capital loss. Always verify current filings, trial data, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
